(A drug manufacturer that produces an acromegaly medication has been purchased by another.)
Endo's acquisition of Indevus has shifted the firm's attention to other specialty markets, such as neurology, endocrinology, and oncology ... Endo is also pursuing the development of ... its octreotide implant, which treats a rare hormonal disorder known as acromegaly.I think my endocrinologist mentioned something like this at my last appointment! Instead of having to go in every 4 weeks for Sandotatin or Somatuline, it would be active for 6 months. He thought the project was being shelved, but if this article is accurate, then it sounds like they will continue working on developing it! Having to go in for medication only 2x a year sounds great, as right now every 4 weeks can be a bit of a hassle.